Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Zepbound Tops Wegovy for Weight Loss
Eli Lilly Chief Scientific Officer explains Zepbound's weight loss advantage
Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins 'Fast Money' to talk Zepbound's recent trial results and what it means for Eli Lilly's future growth.
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.
Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.
Lilly invests $3 billion to expand Wisconsin plant
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound
KENOSHA COUNTY, Wis. (AP) - Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Eli Lilly invests $3 billion to expand Wisconsin factory to help meet demand for blockbuster drugs
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Eli Lilly to Expand Facility to Meet Demand for Diabetes, Obesity Treatments
Drugmaker Eli Lilly plans to invest $3 billion to expand a manufacturing facility in the Kenosha County, Wis., to meet growing demand for its diabetes and weight-loss medicines.
10h
on MSN
Lilly's Zepbound will first be given in the UK to those with 'highest clinical need'
The initial rollout of Eli Lilly's weight loss drug Zepbound in the UK will first go to those with the great clinical need ...
Yahoo Finance
16h
The Weight Loss Drug Race Heats Up: Eli Lilly's Zepbound Outperforms Wegovy in Weight Loss Trials
Eli
Lilly
(NYSE:LLY) has been making headlines recently with its weight-loss drug
Zepbound
(tirzepatide).
Eli
Lilly
...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Tsunami warnings lifted
Images of suspect released
May cut diabetes risk
Nadler to step aside
Billy Long to lead IRS
Set to return after 20 years
Winter storm to hit US
Medellin cartel leader freed
Social Security chief pick
Ethics report release blocked
SpaceX sets record
Weekly jobless claims rise
Satellites to create eclipses
Raw milk recall expands
Recalls over 205,000 SUVs
Judge rejects plea deal
Several prisons to be closed
Biden considers pardons
Joins X Games as CEO
Prenatal test spots cancer?
New AI tools for employees
Syrian rebels capture Hama
Airbus layoffs
US trade deficit shrinks
$10B AI data center in LA
Taiwan's pres visits Guam
Airlines to pay for delays?
Delays oil output hike
Meet with lawmakers
Jury deliberations continue
Sacks to lead AI, crypto
Related topics
Wegovy
Novo Nordisk
Amgen
Glucagon-like peptide-1
Feedback